ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.34% Direct Plan: 0.43%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 19 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	128.75
AAUM (in Rs. Cr):	131.96
% of top 5 holdings:	38.36%
% of top 10 holdings:	60.52%
No. of scrips:	36

Standard Deviation^:	NA
Beta^:	NA
*Sharpe Ratio^:**	NA
Average P/B	5.92
Average P/E	46.68
Portfolio Beta	0.84
^Scheme has not completed 3 years hence NA * Risk free rate: 6.84 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	10.6790	11.1464
IDCW:	10.6790	11.1464

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	98.70
Chemicals	4.45
Vishnu Chemicals Limited	1.76
Astec LifeSciences Limited	1.11
Archean Chemical Industries Limited	0.90
Gujarat Fluorochemicals Limited	0.68
Healthcare	94.25
Sun Pharmaceutical Industries Limited	12.83
Cipla Limited	7.47
Lupin Limited	6.10
Dr. Reddy's Laboratories Limited	6.10
Max Healthcare Institute Limited	5.85
Suven Pharmaceuticals Limited	5.04
Mankind Pharma Limited	4.85
Alkem Laboratories Limited	4.50
Apollo Hospitals Enterprise Limited	3.98
Aurobindo Pharma Limited	3.79
Laurus Labs Limited	3.58
Divi's Laboratories Limited	3.40
Syngene International Limited	3.00
Zydus Lifesciences Limited	2.92
JB Chemicals & Pharmaceuticals Limited	2.23
FDC Limited	1.97
Alembic Pharmaceuticals Limited	1.38
Vijaya Diagnostic Centre Limited	1.32
Ajanta Pharma Limited	1.25
Piramal Pharma Limited	1.19
Sanofi India Limited	1.15
Gland Pharma Limited	1.10
Rainbow Childrens Medicare Limited	1.06
Sun Pharma Advanced Research Company Limited	1.04
Natco Pharma Limited	1.03
Abbott India Limited	1.02
Healthcare Global Enterprises Limited	0.92
Fortis Healthcare Limited	0.90
Sequent Scientific Limited	0.89
Dr. Lal Path Labs Limited	0.85
Ami Organics Limited	0.82
GlaxoSmithKline Pharmaceuticals Limited	0.72
Short Term Debt & Net Current Assets	1.30

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	10.0%	11.0%	7.0%	11,000	11,102	10,701
Since Inception	3.4%	4.4%	4.0%	10,679	10,884	10,812
Direct - Growth
Last 1 Year	12.3%	11.0%	7.0%	11,229	11,102	10,701
Since Inception	5.6%	4.4%	4.0%	11,146	10,884	10,812

Past performance may or may not be sustained in future. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021) . Face Value per unit: Rs. 10.

Period	Amount Invested	Fund Value ()	Fund Returns (%)	Benchmark Value ()	Benchmark Returns (%)	Additional Benchmark Value ()	Additional Benchmark Returns (%)
Regular - Growth
Last 1 Year	1,20,000	1,31,197	17.8%	1,32,653	20.1%	1,24,691	7.3%
Since Inception	2,40,000	2,67,526	10.8%	2,69,409	11.6%	2,60,826	8.2%
Direct - Growth
Last 1 Year	1,20,000	1,32,720	20.2%	1,32,653	20.1%	1,24,691	7.3%
Since Inception	2,40,000	2,73,538	13.2%	2,69,409	11.6%	2,60,826	8.2%

Past performance may or may not be sustained in future. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).